Cameron Reynolds MBAPresident & Chief Executive Officer
Cameron Reynolds is an experienced entrepreneurial executive, with expertise in mining and biotechnology companies. He has strong experience in the management, structuring and strategic planning of start-up companies and has held positions including CEO, CFO and Non-Executive Director of public and private enterprises.
Mr. Reynolds has returned to his life sciences and biotechnology roots where in 1996 he began working for Integrated Coffee Technologies, a genetically modified coffee company, in a junior management position, where he was responsible for business plan creation, office management, recruitment, and business development. After working for Integrated Coffee Technologies, Mr Reynolds served as the commercialization director for Probio, Inc., a company that commercialized intellectual property in the animal biotechnology fields including transgenesis and cloning research from the University of Hawaii. Mr. Reynolds held that role from 1998 until 2001, and his main responsibilities were managing all legal and contract issues with the University of Hawaii; implementing patenting strategy; managing all shareholder issues including the merger and its legal and contractual documentation; head office management; budgetary control; team building and recruitment.
From 2004 until 2011, Mr. Reynolds founded and served as Managing Director and Director of Mining House Limited, where he was responsible for identifying potential mining projects, coordinating the preliminary evaluations and securing the financing with a view to listing the companies on AIM, TSX and US OTC. From 2005 until present, Mr. Reynolds has held a number of board Directorships including Atlantic Mining PLC; Carbon Mining PLC, Magellan Copper and Gold (Carbon Mining and MCG were both became part of Solfotara Mining and Copper Development Corp on AIM, CDC.L after a vend); KAL Energy Inc. (KALG, OTC), Iofina Natural Gas PLC (IOF, AIM); Canyon Copper Corp. (TSX.V: CNC, OTCBB: CNYC), and Hunter Bay Resources (HBY, TSX-V).
Mr. Reynolds was educated at the University of Western Australia (Bachelor of Commerce and MBA).
David Kratochvil MBAChief Financial Officer & Treasurer
David Kratochvil has more than 28 years of broad financial sector experience and leadership. He served as Managing Director of Euro Pacific Capital in the Corporate Finance department, overseeing the firm's investment banking efforts across a variety of sectors. At Euro Pacific since 2008, Mr. Kratochvil also served as Director of Research where he managed a team of equity analysts and increased research coverage.
Prior to Euro Pacific, Mr. Kratochvil had a lengthy career analyzing and investing in international securities. He was an international portfolio manager at Omega Advisors where he analyzed, executed and monitored investments across a variety of asset classes. Prior to joining Omega, he was a Director at Merrill Lynch Asset Management in London where he invested throughout emerging European markets. Additionally, Mr. Kratochvil founded his own advisory firm, Vista Capital Advisors, to provide global investment advice. He also worked as an equity analyst in New York, a private equity investor in Prague, and as a business tax consultant in New York.
Mr. Kratochvil earned a Master of Business Administration (MBA) in Finance and International Business from the University of Chicago's Booth School of Business, and he holds a Bachelor of Science in Economics (BS Econ) with specialization in Finance and Accounting from University of Pennsylvania's Wharton School.
Jake Micallef PhD MBAChief Scientific Officer
Dr. Jake Micallef is an experienced scientific executive with expertise in research and development and in the management of early stage biotechnical companies, including the manufacture of biotechnology products and the establishment of manufacturing operations.
Dr. Micallef gained this experience while working for the World Health Organization (“WHO”) over a 10-year period from 1985. While working for the WHO, Dr. Micallef developed new diagnostic products in the areas of reproductive health and cancer. In 1990 he commenced development of a new diagnostic technology platform for WHO which was launched in 1992 and supported 13 tests. Dr. Micallef also initiated and implemented in-house manufacture (previously outsourced to Abbott Diagnostics Inc) and world-wide distribution of these products for WHO. In 1990, he started a “not-for-profit” WHO company, Immunometrics Ltd., which marketed and distributed those diagnostic products worldwide.
In 1999 Dr. Micallef studied for an MBA and went on to co-found Gene Expression Technologies in 2001 where he successfully lead the development of the chemistry of the GeneICE technology and implemented the manufacture of GeneICE molecules. He also played a major role in business development and procured a GeneICE contract with Bayer Pharmaceuticals.
From 2004 to 2007, he taught Science and Enterprise to science research workers from four universities at CASS Business School before joining Cronos Therapeutics in 2004. In 2006 Cronos was listed in the UK on AIM, becoming ValiRx. Dr. Micallef continued to work as Technical Officer for ValiRx, where he in-licensed the HyperGenomics and Nucleosomics technologies and co-founded ValiBio SA., which is now Belgian Volition SA, a subsidiary of Singapore Volition.
Dr. Micallef was educated at King’s College London (BSc, Biology and Chemistry; PhD Physical Chemistry); St Thomas’ Hospital Medical School, London (MSc Chemical Pathology); and Imperial College Management School (MBA).
Gaetan Michel PhDChief Executive Officer of Belgian Volition SA
Dr. Gaetan Michel has over 10 years experience in production management. Following the completion of his PhD in 2002, Dr. Michel joined AAT (Advanced Array Technology), a University of Namur spin-off company as project manager in proteomics. AAT later became EAT (Eppendorf Array Technology), part of the German Eppendorf Biotech company, where Dr. Michel became production manager and involved in establishing production processes and equipment. From 2007 to 2010 Dr. Michel worked for KitoZyme, a global manufacturer of biopolymers of fungal origin with its core business in weight management, digestive and cardiovascular health. During this period Dr. Michel set up both the production and process development departments and oversaw the commencement of the company’s industrial phase culminating in the roll out of first products. From 2010 to 2014 Dr. Michel worked as production director for Bone Therapeutics – a cell-therapy based pharmaceutical company – where Dr. Michel’s responsibilities included the setup two new production plants to commence manufacturing for two phase III clinical trials, the development of quality systems (GMP) for new products in negotiation with the Belgian health authorities, and the setup of a product plant for an injectable medical device. In light of Dr. Michel’s extensive experience in the area of production management, Dr. Michel was appointed as Chief Operations Officer of Belgian Volition S.A., a wholly owned subsidiary of Volition Rx. In July 2015, Dr. Michel became Chief Executive Officer of Belgian Volition S.A..
Dr. Michel was educated at the University of Namur, Belgium (Chemical Sciences; PhD Biochemical Sciences).
Jason Terrell MDChief Medical Officer & Head of US Operations
Jason Terrell MD is a Texas-based doctor educated at University of Texas and MD Anderson Cancer Center, with expertise in clinical medicine and in the laboratory diagnostics business. Dr. Terrell has a strong grounding in both medicine and more specifically in diagnostics and product commercialization.
Dr. Terrell has both executive and board directorship experience with publicly traded companies in the biotechnology and pharmaceutical industry. Additionally, Dr. Terrell has built and sold multiple private diagnostic laboratories and serves as a National Franchise Corporate Medical Director for Any Lab Test Now, giving him oversight of over 70 franchises in 14 states.
Dr. Terrell was educated at Hardin-Simmons University (Biochemistry), where he graduated Summa Cum Laude, receiving the Holland Medal of Honor as the top graduate in the School of Science and Mathematics. He then attended the University of Texas at Houston Medical School and affiliate MD Anderson Cancer Center (Doctor of Medicine). He undertook his General Medicine Internship, and Anatomic and Clinical Pathology Residency at Texas Tech University Health Sciences Center. In February 2014 Dr. Terrell was recipient of the Outstanding Young Alumni Award from Hardin-Simmons University.
Dr. Terrell holds medical licenses in 14 states across the USA.
Rod Rootsaert LLBCorporate Secretary
Rodney Rootsaert is an experienced legal and corporate secretary with experience providing corporate, legal and administrative services to start-up companies.
From 2007 until 2011, Mr. Rootsaert served as corporate secretary for several junior mining companies. He was the Corporate Secretary for Magellan Copper and Gold Plc., from 2007 until 2011, where his duties included maintaining and preparing company documents, accounts and contracts. He also served as corporate secretary for Delta Pacific Mining Plc., from 2007 until present, where he was responsible for ensuring compliance with all relevant statutory and regulatory requirements.
Mr. Rootsaert was educated at the University of Western Australia (Bachelor of Laws).
Thomas BygottSales & Marketing Director
Thomas Bygott is a sales & marketing professional with experience spearheading sales and marketing for technology companies, as well as a qualified bioinformatician.
Mr. Bygott started his career in sales & marketing with electronics company AWA, moving to Geneva Technology, a Cambridge start-up which was then acquired by Convergys. Mr. Bygott remained with the company as Product Marketing Manager for Europe at Convergys.
Mr. Bygott moved into biotechnology in 2004, studying at Corpus Christi College in Cambridge before joining the Wellcome Trust Sanger Institute as a bioinformatician and Project Manager. He then returned to Sales & Marketing, first as a bioinformatician specializing in genome assembly and then as Project Manager for a resequencing project for malaria parasites.
At Active Motif, a leading supplier of epigenetics research kits, he was Sales and Marketing Manager, Europe for the TimeLogic division, selling specialized hardware to accelerate bioinformatics algorithms at research institutes, biotech companies and universities throughout Europe.
Mr. Bygott was, from 2012 to 2015, a member of the Board of Governors of Cambridge University Hospitals NHS Trust, which operates Addenbrooke's Hospital in Cambridge.
Mr. Bygott was educated at the University of Sydney (BSc in Pure Mathematics), The University of Cambridge (MPhil in Computational Biology) and Cranfield University (MBA)
Mark Eccleston PhD MBABusiness Development Director
Dr. Mark Eccleston is a biotechnology entrepreneur with experience in academia and in industry.
From 2008 to 2009, Dr. Eccleston held a program management position at ValiRx Plc., where he ran multiple epigenetics-based diagnostic and therapeutics programs.
Dr. Eccleston has also held various other roles in business and industry including: CEO of Vivamer Ltd. in 2002, a company spun out from Cambridge University where he was responsible for commercialization of drug delivery and imaging technologies based on extensive work in this area during his academic career; and Chief Scientific Officer then consultant to Cambridge Applied Polymers from 2005 to 2008, where he devised and managed multiple high value consultancy projects for clients including Cadburys, Kellogg’s, Reckitt Benckiser, Proctor and Gamble, and Umbro as well as a Spanish company specializing in non woven (polymeric) fabric, Tesalca.
In 2010, Dr. Eccleston founded OncoLytika, which focuses on opportunity recognition and product/process innovation within start-ups as well as established companies, where his main responsibilities are advising companies on business development and preclinical project management.
Dr. Eccleston was educated at University of Aston in Birmingham, UK (Chemistry, 1992; PhD in Polymer Chemistry (for biomedical applications), 1998); and Dundee University (MBA, Entrepreneurship, 2008; through the Royal Society of Edinburgh’s Enterprise Fellowship Scheme).